A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Naporafenib (Primary) ; Ribociclib (Primary) ; Rineterkib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
Most Recent Events
- 04 Apr 2025 Planned End Date changed from 27 Mar 2025 to 30 Jul 2025.
- 04 Apr 2025 Planned primary completion date changed from 26 Feb 2025 to 30 Jun 2025.
- 20 Dec 2024 Planned End Date changed from 27 Dec 2024 to 27 Mar 2025.